XML 39 R31.htm IDEA: XBRL DOCUMENT
v3.20.1

Reportable segments | 12 Months Ended
--- | ---
Dec. 31, 2019
Disclosure of entity's operating segments [Abstract] |
Disclosure Of Entitys Reportable Segments Explanatory [Text Block] | Note 25 Reportable segments 25.1 Reportable segments
| (a) | General information:
The amount of each item presented in each operating segment is equal to that reported to the highest authority that makes decisions regarding the operation, in order to decide on the allocation of resources to the defined segments and to assess its performance. These operating segments mentioned are consistent with the way the Company is managed and how results will be reported by the Company. These segments reflect separate operating results that are regularly reviewed by the executive responsible for operational decisions in order to make decisions about the resources to be allocated to the segment and assess its performance (See Note 25.2). The performance of each segment is measured based on net income and revenues. Inter-segment sales are made using terms and conditions at current market rates.
| (b) | Factors used to identify segments on which a report should be presented:
The segments covered in the report are strategic business units that offer different products and services. These are managed separately because each business requires different technology and marketing strategies.
| (c) | Description of the types of products and services from which each reportable segment obtains its income from ordinary activities
The operating segments, which obtain income from ordinary activities, generate expenses and have its operating results reviewed on a regular basis by the highest authority who makes decisions regarding operations, relate to the following groups of products: 1. Specialty plant nutrients 2. Iodine and its derivatives 3. Lithium and its derivatives 4. Industrial chemicals 5. Potassium 6. Other products and services
| (d) | Description of income sources for all the other segments
Information regarding assets, liabilities, profits and expenses that cannot be assigned to the segments indicated above, due to the nature of production processes, is included under the "Unallocated amounts” category of the disclosed information.
| (e) | Basis of accounting for transactions between reportable segments
Inter-segment sales are made under the same conditions as sales to third parties and are measured consistently as presented in the statement of income.
| (f) | Description of the nature of the differences between measurements of results of reportable segments and the result of the entity before the expense or income tax expense of incomes and discontinued operations
The information reported in the segments is extracted from the Company’s consolidated financial statements and therefore there is no need to prepare reconciliations between the data mentioned above and those reported in the respective segments, according to what is stated in paragraph 28 of IFRS 8, "Operating Segments". For the allocation of inventory valuation costs, we identify the direct expenses (can be directly allocated to products) and the common expenses (belong to coproduction processes, for example common leaching expenses for production of Iodine and Nitrates), Direct costs are directly allocated to the product and the common costs are distributed according to percentages that consider different variables in their determination, such as margins, rotation of inventories, revenue, production and etc . The allocation of other common costs that are not included in the inventory valuation process, but go straight to the cost of sales, use similar criteria: the costs associated with a product or sales in particular are assigned to that particular product or sales, and the common costs associated with different products or business lines are allocated according to the sales.
| (g) | Description of the nature of the differences between measurements of assets of reportable segments and the Company´s assets
Assets are not shown classified by segments, as this information is not readily available, Some of these assets are not separable by the type of activity by which they are affected since this information is not used by management in decision-making with respect to resources to be allocated to each defined segment. All assets are disclosed in the "unallocated amounts" category.
| (h) | Description of the nature of the differences between measurements of liabilities of reportable segments and the Company’s liabilities
Liabilities are not shown classified by segments, as this information is not readily available, Some of these liabilities are not separable by the type of activity by which they are affected, since this information is not used by management in decision-making regarding resources to be allocated to each defined segment. All liabilities are disclosed in the "unallocated amounts" category.
25.2 Reportable segment disclosures:
Operating segments for the year ended December ‎ 31, 2019 |  | Specialty ‎ plant ‎ nutrients |  |  | Iodine and its ‎ derivatives |  |  | Lithium and ‎ its derivatives |  |  | Industrial ‎ chemicals |  |  | Potassium |  |  | Other ‎ products and ‎ services |  |  | Reportable ‎ segments |  |  | Operating ‎ segments |  |  | Unallocated ‎ amounts |  |  | Total as of ‎ December 31, ‎ 2019 |
|  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |
Revenue |  |  | 723,920 |  |  |  | 371,020 |  |  |  | 505,714 |  |  |  | 94,875 |  |  |  | 212,151 |  |  |  | 35,975 |  |  |  | 1,943,655 |  |  |  | 1,943,655 |  |  |  | - |  |  |  | 1,943,655 |
Revenues from transactions with other operating segments of the same entity |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Revenues |  |  | 723,920 |  |  |  | 371,020 |  |  |  | 505,714 |  |  |  | 94,875 |  |  |  | 212,151 |  |  |  | 35,975 |  |  |  | 1,943,655 |  |  |  | 1,943,655 |  |  |  | - |  |  |  | 1,943,655 |
Costs of sales |  |  | (573,808 | ) |  |  | (230,468 | ) |  |  | (306,250 | ) |  |  | (63,590 | ) |  |  | (176,199 | ) |  |  | (33,288 | ) |  |  | (1,383,603 | ) |  |  | (1,383,603 | ) |  |  | - |  |  |  | (1,383,603 | )
Administrative expenses |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (117,180 | ) |  |  | (117,180 | )
Interest expense |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (76,939 | ) |  |  | (76,939 | )
Depreciation and amortization expense |  |  | (68,007 | ) |  |  | (43,533 | ) |  |  | (45,443 | ) |  |  | (6,885 | ) |  |  | (37,862 | ) |  |  | (534 | ) |  |  | (202,264 | ) |  |  | (202,264 | ) |  |  | - |  |  |  | (202,264 | )
The entity’s interest in the profit or loss of associates and joint ventures accounted for by the equity method |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 9,786 |  |  |  | 9,786 |
Income tax expense, continuing operations |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (110,019 | ) |  |  | (110,019 | )
Income (loss) before taxes |  |  | 150,112 |  |  |  | 140,552 |  |  |  | 199,464 |  |  |  | 31,285 |  |  |  | 35,952 |  |  |  | 2,687 |  |  |  | 560,052 |  |  |  | 560,052 |  |  |  | (169,430 | ) |  |  | 390,622 |
Net profit |  |  | 150,112 |  |  |  | 140,552 |  |  |  | 199,464 |  |  |  | 31,285 |  |  |  | 35,952 |  |  |  | 2,687 |  |  |  | 560,052 |  |  |  | 560,052 |  |  |  | (279,449 | ) |  |  | 280,603 |
Assets |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 4,684,151 |  |  |  | 4,684,151 |
Equity-accounted investees |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 109,435 |  |  |  | 109,435 |
Incorporation of non-current assets other than financial instruments, deferred tax assets, net defined benefit assets and rights arising from insurance contracts |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 124,569 |  |  |  | 124,569 |
Increase of non-current assets |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Liabilities |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 2,549,679 |  |  |  | 2,549,679 |
Impairment loss recognized in profit or loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (1,057 | ) |  |  | (1,057 | )
Reversal of impairment losses recognized in profit or loss for the period |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Cash flows from (used in) operating activities |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 426,971 |  |  |  | 426,971 |
Cash flows from (used in) investing activities |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (485,471 | ) |  |  | (485,471 | )
Cash flows from (used in) financing activities |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 105,896 |  |  |  | 105,896 |
Operating segments for the year ended December ‎ 31, 2018 |  | Specialty ‎ plant ‎ nutrients |  |  | Iodine and its ‎ derivatives |  |  | Lithium and its ‎ derivatives |  |  | Industrial ‎ chemicals |  |  | Potassium |  |  | Other ‎ products and ‎ services |  |  | Reportable ‎ segments |  |  | Operating ‎ segments |  |  | Unallocated ‎ amounts |  |  | Total as of ‎ December 31, ‎ 2018 |
|  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |
Revenue |  |  | 781,751 |  |  |  | 324,972 |  |  |  | 734,801 |  |  |  | 108,267 |  |  |  | 267,474 |  |  |  | 48,538 |  |  |  | 2,265,803 |  |  |  | 2,265,803 |  |  |  | - |  |  |  | 2,265,803 |
Revenues from transactions with other operating segments of the same entity |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Revenues |  |  | 781,751 |  |  |  | 324,972 |  |  |  | 734,801 |  |  |  | 108,267 |  |  |  | 267,474 |  |  |  | 48,538 |  |  |  | 2,265,803 |  |  |  | 2,265,803 |  |  |  | - |  |  |  | 2,265,803 |
Costs of sales |  |  | (613,267 | ) |  |  | (217,464 | ) |  |  | (316,875 | ) |  |  | (72,964 | ) |  |  | (217,386 | ) |  |  | (47,675 | ) |  |  | (1,485,631 | ) |  |  | (1,485,631 | ) |  |  | - |  |  |  | (1,485,631 | )
Administrative expenses |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (118,126 | ) |  |  | (118,126 | )
Interest expense |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (57,807 | ) |  |  | (57,807 | )
Depreciation and amortization expense |  |  | (79,061 | ) |  |  | (42,438 | ) |  |  | (42,283 | ) |  |  | (8,454 | ) |  |  | (47,940 | ) |  |  | (651 | ) |  |  | (220,827 | ) |  |  | (220,827 | ) |  |  | - |  |  |  | (220,827 | )
The entity’s interest in the profit or loss of associates and joint ventures accounted for by the equity method |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 6,351 |  |  |  | 6,351 |
Income tax expense, continuing operations |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (178,975 | ) |  |  | (178,975 | )
Income (loss) before taxes |  |  | 168,484 |  |  |  | 107,508 |  |  |  | 417,926 |  |  |  | 35,303 |  |  |  | 50,088 |  |  |  | 863 |  |  |  | 780,172 |  |  |  | 780,172 |  |  |  | (159,134 | ) |  |  | 621,038 |
Net income (loss)profit |  |  | 168,484 |  |  |  | 107,508 |  |  |  | 417,926 |  |  |  | 35,303 |  |  |  | 50,088 |  |  |  | 863 |  |  |  | 780,172 |  |  |  | 780,172 |  |  |  | (338,109 | ) |  |  | 442,063 |
Assets |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 4,268,094 |  |  |  | 4,268,094 |
Equity-accounted investees |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 111,549 |  |  |  | 111,549 |
Incorporation of non-current assets other than financial instruments, deferred tax assets, net defined benefit assets and rights arising from insurance contracts |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (15,028 | ) |  |  | (15,028 | )
Increase of non-current assets |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Liabilities |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 2,130,292 |  |  |  | 2,130,292 |
Impairment loss recognized in profit or loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 2,967 |  |  |  | 2,967 |
Reversal of impairment losses recognized in profit or loss for the period |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Cash flows from (used in) operating activities |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 524,839 |  |  |  | 524,839 |
Cash flows from (used in) investing activities |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (187,004 | ) |  |  | (187,004 | )
Cash flows from (used in) financing activities |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (387,313 | ) |  |  | (387,313 | )
Operating segments for the year ended December ‎ 31, 2017 |  | Specialty ‎ plant ‎ nutrients |  |  | Iodine and its ‎ derivatives |  |  | Lithium and ‎ its derivatives |  |  | Industrial ‎ chemicals |  |  | Potassium |  |  | Other ‎ products and ‎ services |  |  | Reportable ‎ segments |  |  | Operating ‎ segments |  |  | Unallocated ‎ amounts |  |  | Total as of ‎ December ‎ 31, 2017 |
|  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |
Revenue |  |  | 697,251 |  |  |  | 252,123 |  |  |  | 644,573 |  |  |  | 135,578 |  |  |  | 379,326 |  |  |  | 48,472 |  |  |  | 2,157,323 |  |  |  | 2,157,323 |  |  |  | - |  |  |  | 2,157,323 |
Revenues from transactions with other operating segments of the same entity |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Revenues |  |  | 697,251 |  |  |  | 252,123 |  |  |  | 644,573 |  |  |  | 135,578 |  |  |  | 379,326 |  |  |  | 48,472 |  |  |  | 2,157,323 |  |  |  | 2,157,323 |  |  |  | - |  |  |  | 2,157,323 |
Costs of sales |  |  | (555,356 | ) |  |  | (199,808 | ) |  |  | (189,242 | ) |  |  | (91,753 | ) |  |  | (313,690 | ) |  |  | (44,973 | ) |  |  | (1,394,822 | ) |  |  | (1,394,822 | ) |  |  | - |  |  |  | (1,394,822 | )
Administrative expenses |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (101,171 | ) |  |  | (101,171 | )
Interest expense |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (50,124 | ) |  |  | (50,124 | )
Depreciation and amortization expense |  |  | (73,702 | ) |  |  | (44,252 | ) |  |  | (18,036 | ) |  |  | (16,050 | ) |  |  | (88,130 | ) |  |  | (356 | ) |  |  | (240,526 | ) |  |  | (240,526 | ) |  |  | - |  |  |  | (240,526 | )
The entity’s interest in the profit or loss of associates and joint ventures accounted for by the equity method |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 14,452 |  |  |  | 14,452 |
Income tax expense, continuing operations |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (166,173 | ) |  |  | (166,173 | )
Income (loss) before taxes |  |  | 141,895 |  |  |  | 52,315 |  |  |  | 455,331 |  |  |  | 43,825 |  |  |  | 65,636 |  |  |  | 3,499 |  |  |  | 762,501 |  |  |  | 762,501 |  |  |  | (167,911 | ) |  |  | 594,590 |
Net income (loss)profit |  |  | 141,895 |  |  |  | 52,315 |  |  |  | 455,331 |  |  |  | 43,825 |  |  |  | 65,636 |  |  |  | 3,499 |  |  |  | 762,501 |  |  |  | 762,501 |  |  |  | (334,084 | ) |  |  | 428,417 |
Assets |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 4,296,236 |  |  |  | 4,296,236 |
Equity-accounted investees |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 152,630 |  |  |  | 152,630 |
Incorporation of non-current assets other than financial instruments, deferred tax assets, net defined benefit assets and rights arising from insurance contracts |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Increase of non-current assets |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Liabilities |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 2,048,768 |  |  |  | 2,048,768 |
Impairment loss recognized in profit or loss |  |  | (15,025 | ) |  |  | 335 |  |  |  | 1,112 |  |  |  | (3,546 | ) |  |  | (240 | ) |  |  | (219 | ) |  |  | (17,583 | ) |  |  | (17,583 | ) |  |  | (14,316 | ) |  |  | (31,899 | )
Reversal of impairment losses recognized in profit or loss for the period |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Cash flows from (used in) operating activities |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 758,272 |  |  |  | 758,272 |
Cash flows from (used in) investing activities |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (248,067 | ) |  |  | (248,067 | )
Cash flows from (used in) financing activities |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (411,920 | ) |  |  | (411,920 | )
25.3 Statement of comprehensive income classified by reportable segments based on groups of products
Items in the statement of comprehensive ‎ income as of December 31, 2019 |  | Specialty ‎ plant ‎ nutrients |  |  | Iodine and its ‎ derivatives |  |  | Lithium and ‎ its ‎ derivatives |  |  | Industrial ‎ chemicals |  |  | Potassium |  |  | Other ‎ products and ‎ services |  |  | Corporate ‎ Unit |  |  | Total ‎ segments and ‎ Corporate unit |
|  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |
Revenue |  |  | 723,920 |  |  |  | 371,020 |  |  |  | 505,714 |  |  |  | 94,875 |  |  |  | 212,151 |  |  |  | 35,975 |  |  |  | - |  |  |  | 1,943,655 |
Cost of sales |  |  | (573,808 | ) |  |  | (230,468 | ) |  |  | (306,250 | ) |  |  | (63,590 | ) |  |  | (176,199 | ) |  |  | (33,288 | ) |  |  | - |  |  |  | (1,383,603 | )
Gross profit |  |  | 150,112 |  |  |  | 140,552 |  |  |  | 199,464 |  |  |  | 31,285 |  |  |  | 35,952 |  |  |  | 2,687 |  |  |  | - |  |  |  | 560,052 |
Other income by function |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 18,218 |  |  |  | 18,218 |
Administrative expenses |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (117,180 | ) |  |  | (117,180 | )
Other expenses by function |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (25,995 | ) |  |  | (25,995 | )
Impairment of gains and review of impairment losses (impairment losses) determined in accordance with IFRS 9 |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (1,057 | ) |  |  | (1,057 | )
Other gains (losses) |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (383 | ) |  |  | (383 | )
Financial income |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 26,289 |  |  |  | 26,289 |
Financial costs |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (76,939 | ) |  |  | (76,939 | )
interest in the profit or loss of associates and joint ventures accounted for by the equity method |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 9,786 |  |  |  | 9,786 |
Exchange differences |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (2,169 | ) |  |  | (2,169 | )
Profit (loss) before taxes |  |  | 150,112 |  |  |  | 140,552 |  |  |  | 199,464 |  |  |  | 31,285 |  |  |  | 35,952 |  |  |  | 2,687 |  |  |  | (169,430 | ) |  |  | 390,622 |
Income tax expense |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (110,019 | ) |  |  | (110,019 | )
Net profit (loss) |  |  | 150,112 |  |  |  | 140,552 |  |  |  | 199,464 |  |  |  | 31,285 |  |  |  | 35,952 |  |  |  | 2,687 |  |  |  | (279,449 | ) |  |  | 280,603 |
Items in the statement of comprehensive ‎ income as of December 31, 2018 |  | Specialty ‎ plant ‎ nutrients |  |  | Iodine and its ‎ derivatives |  |  | Lithium and ‎ its ‎ derivatives |  |  | Industrial ‎ chemicals |  |  | Potassium |  |  | Other ‎ products and ‎ services |  |  | Corporate ‎ Unit |  |  | Total ‎ segments and ‎ Corporate unit |
|  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |
Revenue |  |  | 781,751 |  |  |  | 324,972 |  |  |  | 734,801 |  |  |  | 108,267 |  |  |  | 267,474 |  |  |  | 48,538 |  |  |  | - |  |  |  | 2,265,803 |
Cost of sales |  |  | (613,267 | ) |  |  | (217,464 | ) |  |  | (316,875 | ) |  |  | (72,964 | ) |  |  | (217,386 | ) |  |  | (47,675 | ) |  |  | - |  |  |  | (1,485,631 | )
Gross profit |  |  | 168,484 |  |  |  | 107,508 |  |  |  | 417,926 |  |  |  | 35,303 |  |  |  | 50,088 |  |  |  | 863 |  |  |  | - |  |  |  | 780,172 |
Other incomes by function |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 32,048 |  |  |  | 32,048 |
Administrative expenses |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (118,126 | ) |  |  | (118,126 | )
Other expenses by function |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (36,907 | ) |  |  | (36,907 | )
Impairment of gains and review of impairment losses (impairment losses) determined in accordance with IFRS 9 |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 2,967 |  |  |  | 2,967 |
Other gains (losses) |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 6,404 |  |  |  | 6,404 |
Financial income |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 22,533 |  |  |  | 22,533 |
Financial costs |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (57,807 | ) |  |  | (57,807 | )
interest in the profit or loss of associates and joint ventures accounted for by the equity method |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 6,351 |  |  |  | 6,351 |
Exchange differences |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (16,597 | ) |  |  | (16,597 | )
Profit (loss) before taxes |  |  | 168,484 |  |  |  | 107,508 |  |  |  | 417,926 |  |  |  | 35,303 |  |  |  | 50,088 |  |  |  | 863 |  |  |  | (159,134 | ) |  |  | 621,038 |
Income tax expense |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (178,975 | ) |  |  | (178,975 | )
Net profit (loss) |  |  | 168,484 |  |  |  | 107,508 |  |  |  | 417,926 |  |  |  | 35,303 |  |  |  | 50,088 |  |  |  | 863 |  |  |  | (338,109 | ) |  |  | 442,063 |
Items in the statement of comprehensive ‎ income as of December 31, 2017 |  | Specialty ‎ plant ‎ nutrients |  |  | Iodine and its ‎ derivatives |  |  | Lithium and ‎ its ‎ derivatives |  |  | Industrial ‎ chemicals |  |  | Potassium |  |  | Other ‎ products and ‎ services |  |  | Corporate ‎ Unit |  |  | Total ‎ segments and ‎ Corporate unit |
|  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |
Revenue |  |  | 623,853 |  |  |  | 231,144 |  |  |  | 514,627 |  |  |  | 104,137 |  |  |  | 403,323 |  |  |  | 62,238 |  |  |  | - |  |  |  | 1,939,322 |
Cost of sales |  |  | (478,074 | ) |  |  | (191,298 | ) |  |  | (175,616 | ) |  |  | (67,378 | ) |  |  | (359,477 | ) |  |  | (56,442 | ) |  |  | - |  |  |  | (1,328,285 | )
Gross profit |  |  | 145,779 |  |  |  | 39,846 |  |  |  | 339,011 |  |  |  | 36,759 |  |  |  | 43,846 |  |  |  | 5,796 |  |  |  | - |  |  |  | 611,037 |
Other incomes by function |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 15,202 |  |  |  | 15,202 |
Administrative expenses |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (88,436 | ) |  |  | (88,436 | )
Other expenses by function |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (82,533 | ) |  |  | (82,533 | )
Impairment of gains and review of impairment losses (impairment losses) determined in accordance with IFRS 9 |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 7,198 |  |  |  | 7,198 |
Other gains (losses) |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 679 |  |  |  | 679 |
Financial income |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 10,129 |  |  |  | 10,129 |
Financial costs |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (57,498 | ) |  |  | (57,498 | )
interest in the profit or loss of associates and joint ventures accounted for by the equity method |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 13,047 |  |  |  | 13,047 |
Exchange differences |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 460 |  |  |  | 460 |
Net profit (loss) before taxes |  |  | 145,779 |  |  |  | 39,846 |  |  |  | 339,011 |  |  |  | 36,759 |  |  |  | 43,846 |  |  |  | 5,796 |  |  |  | (181,752 | ) |  |  | 429,285 |
Income tax expense |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (132,965 | ) |  |  | (132,965 | )
Net profit (loss) |  |  | 145,779 |  |  |  | 39,846 |  |  |  | 339,011 |  |  |  | 36,759 |  |  |  | 43,846 |  |  |  | 5,796 |  |  |  | (314,717 | ) |  |  | 296,320 |
25.4 Disclosures on geographical areas As indicated in paragraph 33 of IFRS 8, the entity discloses geographical information on its revenue from operating activities with external customers and from non-current assets that are not financial instruments, deferred income tax assets, assets related to post-employment benefits or rights derived from insurance contracts. 25.5 Disclosures on main customers With respect to the degree of dependency of the Company on its customers, in accordance with paragraph 34 of IFRS 8, the Company has no external customers who individually represent 10% or more of its revenue. Credit risk concentrations with respect to trade and other accounts receivable are limited due to the significant number of entities in the Company’s portfolio and its worldwide distribution. The Company’s policy requires guarantees (such as letters of credit, guarantee clauses and others) and/or to maintain insurance policies for certain accounts as deemed necessary by the Company’s Management.
Items as of December 31, 2019 |  | Chile |  |  | Latin America ‎ and the ‎ Caribbean |  |  | Europe |  |  | North America |  |  | Asia and others |  |  | Total |
|  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |
Revenue |  |  | 211,857 |  |  |  | 161,928 |  |  |  | 393,764 |  |  |  | 451,272 |  |  |  | 724,834 |  |  |  | 1,943,655 |
Investment accounted for under the equity method |  |  | - |  |  |  | (5,175 | ) |  |  | 42,243 |  |  |  | 14,669 |  |  |  | 57,698 |  |  |  | 109,435 |
Intangible assets other than goodwill |  |  | 106,910 |  |  |  | 420 |  |  |  | 1,397 |  |  |  | 2,683 |  |  |  | 76,948 |  |  |  | 188,358 |
Goodwill |  |  | 23,205 |  |  |  | - |  |  |  | 11,521 |  |  |  | - |  |  |  | - |  |  |  | 34,726 |
Property, plant and equipment, net |  |  | 1,559,080 |  |  |  | 513 |  |  |  | 6,241 |  |  |  | 8,333 |  |  |  | 32,903 |  |  |  | 1,607,070 |
Other non-current assets |  |  | 20,321 |  |  |  | 28 |  |  |  | 4 |  |  |  | (624 | ) |  |  | - |  |  |  | 19,729 |
Non-current assets |  |  | 1,709,516 |  |  |  | (4,214 | ) |  |  | 61,406 |  |  |  | 25,061 |  |  |  | 167,549 |  |  |  | 1,959,318 |
Items as of December 31, 2018 |  | Chile |  |  | Latin America ‎ and the ‎ Caribbean |  |  | Europe |  |  | North America |  |  | Asia and others |  |  | Total |
|  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |  |  | ThUS$ |
Revenue |  |  | 189,349 |  |  |  | 180,189 |  |  |  | 479,664 |  |  |  | 471,515 |  |  |  | 945,086 |  |  |  | 2,265,803 |
Investment accounted for under the equity method |  |  | (6,588 | ) |  |  | - |  |  |  | 61,256 |  |  |  | 16,115 |  |  |  | 40,766 |  |  |  | 111,549 |
Intangible assets other than goodwill |  |  | 110,544 |  |  |  | 1,215 |  |  |  | 238 |  |  |  | 152 |  |  |  | 77,201 |  |  |  | 189,350 |
Goodwill |  |  | 22,535 |  |  |  | 86 |  |  |  | 11,521 |  |  |  | 724 |  |  |  | - |  |  |  | 34,866 |
Property, plant and equipment, net |  |  | 1,445,349 |  |  |  | 347 |  |  |  | 4,451 |  |  |  | 3,098 |  |  |  | 1,578 |  |  |  | 1,454,823 |
Other non-current assets |  |  | 17,111 |  |  |  | 23 |  |  |  | - |  |  |  | (892 | ) |  |  | 11,297 |  |  |  | 27,539 |
Non-current assets |  |  | 1,588,951 |  |  |  | 1,671 |  |  |  | 77,466 |  |  |  | 19,197 |  |  |  | 130,842 |  |  |  | 1,818,127 |
25.6 Property, plant and equipment classified by geographical areas The company's main production facilities are located near their mines and extraction facilities in northern Chile. The following table presents the main production facilities as of December 31, 2019 and December 31, 2018:
| Location |  | Products
- | Pedro de Valdivia | : | Production of iodine and nitrate salts
- | María Elena | : | Production of iodine and nitrate salts
- | Coya Sur | : | Production of nitrate salts
- | Nueva Victoria | : | Production of iodine and nitrate salts
- | Salar de Atacama | : | Potassium chloride, lithium chloride, boric acid and potassium sulfate
- | Salar del Carmen | : | Production of lithium carbonate and lithium hydroxide
- | Tocopilla | : | Port facilities

X
- References No definition available. + Details
Name: | sqm_DisclosureOfEntitysOperatingSegmentsAbstract
Namespace Prefix: | sqm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | sqm_DisclosureOfEntitysReportableSegmentsExplanatoryTextBlock
Namespace Prefix: | sqm_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration